The DOI matches its Crossref record; 5 of the 6 references it cites were found in a registry or an index; none of the 2 sources its claims cite is checked for support yet.
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Open accessAbstract
Persistence of Antibody after mRNA-1273 Vaccination A total of 33 participants who received both doses of the Moderna mRNA-1273 vaccine against SARS-CoV-2 had blood drawn over a period of 6 months ...
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
23 Own result · 2 Not checked yet · 1 Own interpretation
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 109 days (95% CI, 92 to 136) calculated with the use of a power-law model (at day 119)”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 66 days (95% CI, 59 to 72) and 182 days (95% CI, 153 to 254) for live-virus neutralization.”
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The estimated half-life of binding antibodies after day 43 for all the participants was 52 days (95% CI, 46 to 58) calculated with the use of an exponential decay model”
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: The exponential decay model assumes a constant antibody decay rate over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The neutralizing antibody half-life estimates in the two models were 69 days (95% CI, 61 to 76) and 173 days (95% CI, 144 to 225) for pseudovirus neutralization”
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: The exponential decay model assumes a constant antibody decay rate over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with 50% inhibitory dilution (ID50) GMTs of 80 (95% CI, 40 to 135), 57 (95% CI, 30 to 106), and 59 (95% CI, 29 to 121), respectively.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“49,373 (95% CI, 25,171 to 96,849) in those 71 years of age or older.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As measured by ΔAICc (change in Akaike information criterion, corrected for small sample size), the best fit for binding and neutralization were the power-law and exponential decay models, respectively”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: The exponential decay model assumes a constant antibody decay rate over time.
- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“62,424 (95% CI, 36,765 to 105,990) in those 56 to 70 years of age”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The neutralizing antibody half-life estimates in the two models were 69 days (95% CI, 61 to 76) and 173 days (95% CI, 144 to 225) for pseudovirus neutralization”
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“these GMTs were lower in participants 56 to 70 years of age (P=0.03) and in those 71 years of age or older (P=0.005) than in those 18 to 55 years of age”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 2
In the paper
“Interim results from a phase 3 trial of the Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine indicated 94% efficacy in preventing coronavirus disease 2019 (Covid-19).1”
What the sources say
- Not checked yetcites [1] Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384: 403- 416. 33378609 PMC7787219 source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“These results are consistent with published observations of convalescent patients with Covid-19 through 8 months after symptom onset.5”
What the sources say
- Not checked yetcites [5] Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021; 371(6529): eabf4063- eabf4063. 33408181 PMC7919858 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
The durability of protection from the mRNA-1273 vaccine is currently unknown.
“The durability of protection is currently unknown.”
The authors state this as an assumption.
The exponential decay model assumes a constant antibody decay rate over time.
“which assumes a steady decay rate over time”
The authors state this as an assumption.
The power-law model assumes that antibody decay rates decrease over time.
“which assumes that decay rates decrease over time”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Current evidence suggests that circulating antibodies persist for at least 6 months postvaccination (7), although there is some decay from the peak levels achieved after the second dose.”
From mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern (2021) · cites this paper as [7]
In the citing paper
“We previously showed that vaccination with mRNA-1273 elicited antibodies to SARS-CoV-2 WA1 in subjects aged 56 to 70 and 71 and older that are as potent (15) and durable (13) as those elicited in adults aged 18 to 55, with a slight decrease in potency for the oldest subjects in live-virus neutralization (13).”
From Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) · cites this paper as [13]
In the citing paper
“In the pseudovirus neutralization assay, consistent with our previous study (13), 25% of sera neutralized WA1 after one dose (day 29).”
From Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) · cites this paper as [13]
In the citing paper
“In clinical trials, two doses of mRNA-1273 also elicited durable antibody responses over a period of 6 months. Although antibody titres declined slightly over the duration of the study, high neutralizing ability was retained across all age groups205.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [205]
In the citing paper
“Several reports have measured the decay of neutralizing antibody responses raised by mRNA COVID-19 vaccines with a half-life of 69-173 days (Doria-Rose et al., 2021; Levin et al., 2021).”
From mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant (2022) · cites this paper as Doria-Rose et al., 2021
Citations
Cites
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Self-citationAn mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Self-citationImmunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citationDurability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
Widge, A. T., Rouphael, N. G., Jackson, L. A., Anderson, E. J., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2032195 · Cited by 722
Self-citation
Cited by
Sorted by citations
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
Garcia-Beltran, W. F., St. Denis, K. J., Hoelzemer, A., Lam, E. C., Nitido, A. D., Sheehan, M. L., Berrios, C., Ofoman, O., Chang, C. C., Hauser, B. M., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.033 · Cited by 1,045
Fiolet, T., Kherabi, Y., MacDonald, C.-J., Ghosn, J., & Peiffer-Smadja, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.005 · Cited by 911
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
Goel, R. R., Painter, M. M., Apostolidis, S. A., Mathew, D., Meng, W., Rosenfeld, A. M., Lundgreen, K. A., Reynaldi, A., Khoury, D. S., Pattekar, A., et al. (2021) · Science · doi:10.1126/science.abm0829 · Cited by 873
Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study
Naaber, P., Tserel, L., Kangro, K., Sepp, E., Jürjenson, V., Adamson, A., Haljasmägi, L., Rumm, A. P., Maruste, R., Kärner, J., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100208 · Cited by 637
T cell responses to SARS-CoV-2 spike cross-recognize Omicron
Keeton, R., Tincho, M. B., Ngomti, A., Baguma, R., Benede, N., Suzuki, A., Khan, K., Cele, S., Bernstein, M. P., Karim, F., et al. (2022) · Nature · doi:10.1038/s41586-022-04460-3 · Cited by 617
Humoral and cellular immune memory to four COVID-19 vaccines
Zhang, Z., Mateus, J., Coelho, C. H., Dan, J. M., Moderbacher, C. R., Gálvez, R. I., Côrtes, F. H., Grifoni, A., Tarke, A., Chang, J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.05.022 · Cited by 576
Systems vaccinology of the BNT162b2 mRNA vaccine in humans
Arunachalam, P. S., Scott, M. K. D., Hagan, T., Li, C., Feng, Y., Wimmers, F., Grigoryan, L., Trisal, M., Edara, V. V., Lai, L., et al. (2021) · Nature · doi:10.1038/s41586-021-03791-x · Cited by 572
Self-citationDurability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
Pegu, A., O’Connell, S. E., Schmidt, S. D., O’Dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K. S., et al. (2021) · Science · doi:10.1126/science.abj4176 · Cited by 527
Self-citationEfficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
Li, Y., Wong, S., Chai, L., Lee, S. C., Lee, M., Muthiah, M. D., Tay, S., Teo, C., Tan, B., Chan, Y., et al. (2022) · British medical journal · doi:10.1136/bmj-2021-068632 · Cited by 446
Cohen, K. W., Linderman, S. L., Moodie, Z., Czartoski, J., Lai, L., Mantus, G., Norwood, C., Nyhoff, L. E., Edara, V. V., Floyd, K., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100354 · Cited by 441
Self-citationCovid-19 Vaccines — Immunity, Variants, Boosters
Barouch, D. H. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2206573 · Cited by 451
Choi, A., Koch, M., Wu, K., Chu, L., Ma, L., Hill, A., Nunna, N., Huang, W., Oestreicher, J., Colpitts, T., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01527-y · Cited by 396
Self-citationEvaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents
Ali, K., Berman, G., Zhou, H., Deng, W., Faughnan, V., Coronado-Voges, M., Ding, B., Dooley, J., Girard, B., Hillebrand, W., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2109522 · Cited by 377
Self-citationZeng, G., Wu, Q., Pan, H., Li, M., Yang, J., Wang, L., Wu, Z., Jiang, D., Deng, X., Chu, K., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00681-2 · Cited by 319
SARS-CoV-2 Variants, Vaccines, and Host Immunity
Mistry, P., Barmania, F., Mellet, J., Peta, K. T., Strydom, A., Viljoen, I. M., James, W., Gordon, S., & Pepper, M. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.809244 · Cited by 314
Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging
Jung, H. N., Lee, S.-Y., Lee, S., Youn, H., & Im, H.-J. (2022) · Theranostics · doi:10.7150/thno.77259 · Cited by 282
Immunological memory to SARS‐CoV ‐2 infection and COVID ‐19 vaccines
Sette, A., & Crotty, S. (2022) · Immunological Reviews · doi:10.1111/imr.13089 · Cited by 270
mRNA Vaccines in the COVID-19 Pandemic and Beyond
Hogan, M. J., & Pardi, N. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042420-112725 · Cited by 260
Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination
Barouch, D. H., Stephenson, K. E., Sadoff, J., Yu, J., Chang, A., Gebre, M., McMahan, K., Liu, J., Chandrashekar, A., Patel, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2108829 · Cited by 237
SARS-CoV-2 vaccine protection and deaths among US veterans during 2021
Cohn, B. A., Cirillo, P. M., Murphy, C. C., Krigbaum, N. Y., & Wallace, A. W. (2021) · Science · doi:10.1126/science.abm0620 · Cited by 233
Review of COVID-19 vaccine subtypes, efficacy and geographical distributions
Francis, A. I., Ghany, S., Gilkes, T., & Umakanthan, S. (2021) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2021-140654 · Cited by 216
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations
Grainger, R., Kim, A. H. J., Conway, R. P., Yazdany, J., & Robinson, P. C. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00755-x · Cited by 193
Immunity to SARS‐CoV‐2 induced by infection or vaccination
Dopico, X. C., Ols, S., Loré, K., & Hedestam, G. B. K. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13372 · Cited by 172
Antibody titres decline 3-month post-vaccination with BNT162b2
Favresse, J., Bayart, J., Mullier, F., Elsen, M., Eucher, C., Eeckhoudt, S. V., Roy, T., Wieërs, G., Laurent, C., Dogné, J., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1953403 · Cited by 151
Oosting, S. F., van der Veldt, A. A. M., GeurtsvanKessel, C. H., Fehrmann, R. S. N., van Binnendijk, R. S., Dingemans, A. C., Smit, E. F., Hiltermann, T. J. N., den Hartog, G., Jalving, M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00574-x · Cited by 150
Antibody-mediated neutralization of SARS-CoV-2
Gruell, H., Vanshylla, K., Weber, T., Barnes, C. O., Kreer, C., & Klein, F. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.005 · Cited by 150
Extended interval BNT162b2 vaccination enhances peak antibody generation
Parry, H., Bruton, R. K., Stephens, C., Bentley, C., Brown, K. E., Amirthalingam, G., Hallis, B., Otter, A. D., Zuo, J., & Moss, P. A. H. (2022) · npj Vaccines · doi:10.1038/s41541-022-00432-w · Cited by 146
Notarte, K. I., Guerrero‐Arguero, I., Velasco, J. V., Ver, A. T., de Oliveira, M. H. S., Catahay, J. A., Khan, M. S. R., Pastrana, A. M., Juszczyk, G., Torrelles, J. B., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27688 · Cited by 145
Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy
Jiang, Y.-Z., Rubin, L., Peng, T., Liu, L., Xing, X., Lazarovici, P., & Zheng, W. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59272 · Cited by 144
COVID-19 in patients with hematologic malignancy
Langerbeins, P., & Hallek, M. J. (2022) · Blood · doi:10.1182/blood.2021012251 · Cited by 143
Čiučiulkaitė, I., Möhlendick, B., Thümmler, L., Fisenkci, N., Elsner, C., Dittmer, U., Siffert, W., & Lindemann, M. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.932043 · Cited by 132
An intranasal vaccine durably protects against SARS-CoV-2 variants in mice
Hassan, A. O., Shrihari, S., Gorman, M. J., Ying, B., Yuan, D., Raju, S., Chen, R. E., Dmitriev, I. P., Kashentseva, E. A., Adams, L. J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109452 · Cited by 131
Self-citationWong, L. P., Alias, H., Danaee, M., Ahmed, J., Lachyan, A. S., Cai, C. Z., Lin, Y., Hu, Z., Tan, S. Y., Lu, Y., et al. (2021) · Infectious Diseases of Poverty · doi:10.1186/s40249-021-00900-w · Cited by 134
Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine
Liu, Y., Zeng, Q., Deng, C., Li, M., Li, L., Liu, D., Liu, M., Ruan, X., Mei, J., Mo, R., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00373-7 · Cited by 123
Lew, T. T. S., Aung, K. M. M., Ow, S. Y., Amrun, S. N., Sutarlie, L., Ng, L. F. P., & Su, X. (2021) · ACS Nano · doi:10.1021/acsnano.1c04091 · Cited by 116
Chen, X., Chen, Z., Azman, A. S., Sun, R., Lu, W., Zheng, N., Zhou, J., Wu, Q., Deng, X., Zhao, Z., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab646 · Cited by 113
Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
Bates, T. A., Leier, H. C., Lyski, Z. L., McBride, S. K., Coulter, F. J., Weinstein, J. B., Goodman, J. R., Lu, Z., Siegel, S. A. R., Sullivan, P. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25479-6 · Cited by 115
Antibody titers and protection against a SARS-CoV-2 infection
Dimeglio, C., Hérin, F., Martin‐Blondel, G., Miédougé, M., & Izopet, J. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.09.013 · Cited by 113
Liu, Z., Zhou, J., Xu, W., Deng, W., Wang, Y., Wang, M., Wang, Q., Hsieh, M. K., Dong, J., Wang, X., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00612-2 · Cited by 113
Tan, A. T., Lim, J. M. E., Bert, N. L., Kunasegaran, K., Chia, A., Qui, M., Tan, N., Chia, W. N., de Alwis, R., Ying, D., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152379 · Cited by 110
COVID-19 vaccine – Long term immune decline and breakthrough infections
Khoury, J., Najjar‐Debbiny, R., Hanna, A., Jabbour, A. R., Ahmad, Y. A., Saffuri, A., Abu-Sinni, M., Shkeiri, R., Elemy, A., & Hakim, F. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.10.038 · Cited by 110
Tauzin, A., Gong, S. Y., Beaudoin-Bussières, G., Vézina, D., Gasser, R., Nault, L., Marchitto, L., Benlarbi, M., Chatterjee, D., Nayrac, M., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.12.004 · Cited by 106
Durability of immune responses to mRNA booster vaccination against COVID-19
Arunachalam, P. S., Lai, L., Samaha, H., Feng, Y., Hu, M., Hui, H. S.-Y., Wali, B., Ellis, M. L., Davis-Gardner, M. E., Huerta, C., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167955 · Cited by 105
Self-citationPrevious COVID-19 Infection and Antibody Levels After Vaccination
Ali, H., Alahmad, B., Al‐Shammari, A. A., Alterki, A., Hammad, M. M., Cherian, P., Al‐Khairi, I., Sindhu, S. T. A. K., Thanaraj, T. A., Mohammad, A., et al. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.778243 · Cited by 100
Pascarella, S., Ciccozzi, M., Zella, D., Bianchi, M., Benedetti, F., Benvenuto, D., Broccolo, F., Cauda, R., Caruso, A., Angeletti, S., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27210 · Cited by 100
Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates
Corbett, K. S., Gagné, M., Wagner, D. A., Connell, S. O., Narpala, S., Flebbe, D. R., Andrew, S. F., Davis, R. L., Flynn, B. J., Johnston, T. S., et al. (2021) · Science · doi:10.1126/science.abl8912 · Cited by 98
Self-citationCurrent and future nanoparticle vaccines for COVID-19
Vu, M. N., Kelly, H. G., Kent, S. J., & Wheatley, A. K. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103699 · Cited by 101
Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans
Haveri, A., Ekström, N., Solastie, A., Virta, C., Österlund, P., Isosaari, E., Nohynek, H., PALMU, A. A. I., & Melin, M. M. (2021) · European Journal of Immunology · doi:10.1002/eji.202149535 · Cited by 92
Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster
Wu, K., Choi, A., Koch, M., Ma, L., Hill, A., Nunna, N., Huang, W., Oestreicher, J., Colpitts, T., Bennett, H., et al. (2021) · doi:10.1101/2021.05.05.21256716 · Cited by 84
Self-citationMarjot, T., Eberhardt, C. S., Boettler, T., Belli, L. S., Berenguer, M., Buti, M., Jalan, R., Mondelli, M. U., Moreau, R., Shouval, D., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.008 · Cited by 84
Tretyn, A., Szczepanek, J., Skorupa, M., Jarkiewicz‐Tretyn, J., Sandomierz, D., Dejewska, J., Ciechanowska, K., Jarkiewicz-Tretyn, A., Koper, W., & Pałgan, K. (2021) · Cells · doi:10.3390/cells10081952 · Cited by 85
Wang, C. Y., Hwang, K.-P., Kuo, H.-K., Peng, W.-J., Shen, Y.-H., Kuo, B.-S., Huang, J.-H., Liu, H., Ho, Y.-H., Lin, F., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157707 · Cited by 82
Biological Nanoparticles in Vaccine Development
Curley, S. M., & Putnam, D. A. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.867119 · Cited by 77
Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge
Muruato, A. E., Vu, M. N., Johnson, B. A., Davis-Gardner, M. E., Vanderheiden, A., Lokugamage, K. G., Schindewolf, C., Crocquet-Valdes, P. A., Langsjoen, R. M., Plante, J. A., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001284 · Cited by 77
Self-citationNiessl, J., Sekine, T., & Buggert, M. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101505 · Cited by 77
Thuluva, S., Paradkar, V. M., Gunneri, S., Yerroju, V., Mogulla, R. R., Turaga, K., Kyasani, M., Manoharan, S. K., Medigeshi, G. R., Singh, J., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104217 · Cited by 76
Lim, J. M. E., Hang, S. K., Hariharaputran, S., Chia, A., Tan, N., Lee, E. S., Chng, E., Lim, P. L., Young, B. E., Lye, D. C., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100793 · Cited by 73
Moncunill, G., Aguilar, R., Ribes, M., Ortega, N., Rubio, R., Salmerón, G., Molina, M. J., Vidal, M., Barrios, D., Mitchell, R. A., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2021.103805 · Cited by 74
Gagné, M., Corbett, K. S., Flynn, B. J., Foulds, K. E., Wagner, D. A., Andrew, S. F., Todd, J.-P. M., Honeycutt, C. C., McCormick, L., Nurmukhambetova, S. T., et al. (2021) · Cell · doi:10.1016/j.cell.2021.12.002 · Cited by 71
Self-citationMaeda, K., Amano, M., Uemura, Y., Tsuchiya, K., Matsushima, T., Noda, K., Shimizu, Y., Fujiwara, A., Takamatsu, Y., Ichikawa, Y., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-01930-y · Cited by 72
Bajema, K. L., Dahl, R. M., Evener, S. L., Prill, M. M., Rodriguez‐Barradas, M. C., Marconi, V. C., Beenhouwer, D. O., Holodniy, M., Lucero-Obusan, C. A., Brown, S. T., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7049a2 · Cited by 72
Lau, E. H. Y., Hui, D. S. C., Tsang, O. T., Chan, W. H., Kwan, M. Y. W., Chiu, S. S. S., Cheng, S. M. S., Ko, R. L., Li, J. K., Chaothai, S., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101174 · Cited by 71
Brufau, S. R., Chopra, A., Ryu, A. J., Gel, E. S., Raskar, R., Kremers, W. K., Anderson, K. S., Subramanian, J., Krishnamurthy, B., Singh, A., et al. (2021) · BMJ · doi:10.1136/bmj.n1087 · Cited by 71
Tré‐Hardy, M., Cupaiolo, R., Wilmet, A., Antoine-Moussiaux, T., Vecchia, A. D., Horeanga, A., Papleux, E., Vekemans, M., Beukinga, I., & Blairon, L. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.08.031 · Cited by 70
COVID ‐19: vaccination problems
Brüssow, H. (2021) · Environmental Microbiology · doi:10.1111/1462-2920.15549 · Cited by 69
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
Ludwig, H., Sonneveld, P., Facon, T. T. F., Miguel, J. F. S., Avet‐Loiseau, H., Mohty, M., Mateos, M.-V., Moreau, P., Cavo, M., Pawlyn, C., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00278-7 · Cited by 66
Defending against SARS-CoV-2: The T cell perspective
Almendro-Vázquez, P., Laguna‐Goya, R., & Paz‐Artal, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1107803 · Cited by 67
Therapeutic cancer vaccines revamping: technology advancements and pitfalls
Antonarelli, G., Corti, C., Tarantino, P., Ascione, L., Cortés, J., Romero, P. J., Mittendorf, E., Disis, M. L., & Curigliano, G. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2153 · Cited by 64
Durability of immune responses to the BNT162b2 mRNA vaccine
Suthar, M. S., Arunachalam, P. S., Hu, M., Reis, N., Trisal, M., Raeber, O., Chinthrajah, R. S., Davis-Gardner, M. E., Manning, K. E., Mudvari, P., et al. (2022) · Med · doi:10.1016/j.medj.2021.12.005 · Cited by 63
Self-citationSix-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors
Waldhorn, I., Holland, R., Goshen‐Lago, T., Shirman, Y., Szwarcwort‐Cohen, M., Benaim, A. R., Shachor‐Meyouhas, Y., Hussein, K., Fahoum, L., Peer, A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1072 · Cited by 60
Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months
Hsu, C. M., Weiner, D. E., Manley, H. J., Aweh, G. N., Ladik, V., Frament, J., Miskulin, D., Agyropoulos, C., Abreo, K. D., Chin, A., et al. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12250921 · Cited by 60
Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · Nature · doi:10.1038/s41586-024-08511-9 · Cited by 61
Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa
Reddy, K. P., Fitzmaurice, K. P., Scott, J. A., Harling, G., Lessells, R. J., Panella, C., Shebl, F. M., Freedberg, K. A., & Siedner, M. J. (2021) · Nature Communications · doi:10.1038/s41467-021-26557-5 · Cited by 62
Americo, J. L., Cotter, C. A., Earl, P. L., Liu, R., & Moss, B. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2202069119 · Cited by 60
COVID-19 Vaccination in Pregnancy and Lactation: Current Research and Gaps in Understanding
Shook, L. L., Fallah, P. N., Silberman, J. N., & Edlow, A. G. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.735394 · Cited by 59
Durability of Heterologous and Homologous COVID-19 Vaccine Boosts
Tan, C. S., Collier, A.-R. Y., Yu, J., Liu, J., Chandrashekar, A., McMahan, K., Jacob-Dolan, C., He, X., Roy, V., Hauser, B. M., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.26335 · Cited by 57
Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine
Jeewandara, C., Aberathna, I. S., Pushpakumara, P. D., Kamaladasa, A., Guruge, D., Wijesinghe, A., Gunasekera, B., Ramu, S. T., Kuruppu, H., Ranasinghe, T., et al. (2022) · Immunity Inflammation and Disease · doi:10.1002/iid3.621 · Cited by 55
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
Fang, Z., Peng, L., Filler, R. B., Suzuki, K., McNamara, A., Lin, Q., Renauer, P. A., Yang, L., Menasché, B. L., Sanchez, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30878-4 · Cited by 55
Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape
Lou, F., Li, M., Pang, Z., Jiang, L., Guan, L., Tian, L., Hu, J., Fan, J., & Fan, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.744242 · Cited by 54
The way of SARS-CoV-2 vaccine development: success and challenges
Dong, Y., Dai, T., Wang, B., Zhang, L., Zeng, L., Huang, J., Yan, H., Zhang, L., & Zhou, F. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00796-w · Cited by 53
Delivery Routes for COVID-19 Vaccines
Park, J. H., & Lee, H. K. (2021) · Vaccines · doi:10.3390/vaccines9050524 · Cited by 53
Pang, A. P. S., Higgins‐Chen, A., Comite, F., Raica, I., Arboleda, C., Went, H., Mendez, T. L., Schotsaert, M., Dwaraka, V. B., Smith, R. C., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.819749 · Cited by 53
Nanomechanical action opens endo-lysosomal compartments
Zhao, Y., Ye, Z., Song, D., Wich, D., Gao, S., Khirallah, J., & Xu, Q. (2023) · Nature Communications · doi:10.1038/s41467-023-42280-9 · Cited by 52
Sanders, J., Messchendorp, A. L., de Vries, R. D., Baan, C. C., van Baarle, D., van Binnendijk, R. S., Diavatopoulos, D. A., Geers, D., Schmitz, K. S., GeurtsvanKessel, C. H., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac557 · Cited by 51
Arunachalam, P. S., Feng, Y., Ashraf, U., Hu, M., Walls, A. C., Edara, V. V., Zarnitsyna, V. I., Aye, P. P., Golden, N., Miranda, M. C., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq4130 · Cited by 53
Self-citationLozano‐Rodríguez, R., Valentín‐Quiroga, J., Ortiz, J. A., Martín‐Quirós, A., Pascual‐Iglesias, A., Terrón‐Arcos, V., Montalbán-Hernández, K. M., Casalvilla‐Dueñas, J. C., Bergón-Gutiérrez, M., Alcamı́, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110235 · Cited by 50
Routhu, N. K., Gangadhara, S., Lai, L., Davis-Gardner, M. E., Floyd, K. A., Shiferaw, A., Bartsch, Y. C., Fischinger, S., Khoury, G., Rahman, S. A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo0226 · Cited by 51
Self-citationAre COVID-19 Vaccine Boosters Needed? The Science behind Boosters
Burckhardt, R. M., Dennehy, J. J., Poon, L. L. M., Saif, L. J., & Enquist, L. W. (2021) · Journal of Virology · doi:10.1128/jvi.01973-21 · Cited by 52
Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2
Lake, D. F., Roeder, A. J., Kaleta, E. J., Jasbi, P., Pfeffer, K., Koelbela, C., Periasamy, S., Kuzmina, N. A., Bukreyev, A. A., Grys, T. E., et al. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.105024 · Cited by 49
Humoral immune response of BBIBP COVID‐19 vaccination before and after the booster immunization
Cheng, Z. J., Huang, H., Zheng, P., Xue, M., Ma, J., Zhan, Z., Gan, H., Zeng, Y., Lin, R., Li, S., et al. (2022) · Allergy · doi:10.1111/all.15271 · Cited by 49
Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
Ao, L., Lu, T., Cao, Y., Chen, Z., Wang, Y., Li, Z., Ren, X., Xu, P., Peng, M., Chen, M., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2059401 · Cited by 49
Shimizu, J., Sasaki, T., Koketsu, R., Morita, R., Yoshimura, Y., Murakami, A., Saito, Y., Kusunoki, T., Samune, Y., Nakayama, E. E., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-19993-w · Cited by 50
Valanparambil, R. M., Carlisle, J. W., Linderman, S. L., Akhtar, A., Millett, R. L., Lai, L., Chang, A., McCook‐Veal, A. A., Switchenko, J. M., Nasti, T. H., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02986 · Cited by 48
Self-citationDurability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment
Eliakim‐Raz, N., Massarweh, A., Stemmer, A., & Stemmer, S. M. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.4390 · Cited by 48
Brisotto, G., Muraro, E., Montico, M., Corso, C., Evangelista, C., Casarotto, M., Caffau, C., Vettori, R., Cozzi, M. R., Zanussi, S., et al. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.10.035 · Cited by 48
How long does covid-19 immunity last?
Baraniuk, C. (2021) · BMJ · doi:10.1136/bmj.n1605 · Cited by 45
Tomalka, J. A., Suthar, M. S., Deeks, S. G., & Sékaly, R. (2022) · Nature Immunology · doi:10.1038/s41590-022-01130-4 · Cited by 45
Self-citationYin, J., Chen, Y., Li, Y., Wang, C., & Zhang, X. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.10.005 · Cited by 45
Metadata
- Authors
- Doria-Rose, N., Suthar, M. S., Makowski, M., O’Connell, S., McDermott, A. B., Flach, B., Ledgerwood, J. E., Mascola, J. R., Graham, B. S., Lin, B. C., O’Dell, S., Schmidt, S. D., Widge, A. T., Edara, V.-V., Anderson, E. J., Lai, L., Floyd, K., Rouphael, N. G., Zarnitsyna, V., Roberts, P. C., Makhene, M., Buchanan, W., Luke, C. J., Beigel, J. H., Jackson, L. A., Neuzil, K. M., Bennett, H., Leav, B., Albert, J., & Kunwar, P.
- Affiliations
- National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD
- Emory University (US)
- Emmes (United States) (US)
- National Institutes of Health (US)
- NIAID, Bethesda, MD
- Kaiser Permanente Washington Health Research Institute (US)
- University of Maryland, Baltimore (US)
- Moderna Therapeutics (United States) (US)
- Corresponding author
- Suthar, Mehul S.
- ORCID
- Doria-Rose, Nicole
- Suthar, Mehul S.
- Makowski, Mat
- O’Connell, Sarah
- McDermott, Adrian B.
- Ledgerwood, Julie E.
- Mascola, John R.
- Graham, Barney S.
- Lin, Bob C.
- Schmidt, Stephen D.
- Widge, Alicia T.
- Edara, Venkata-Viswanadh
- Anderson, Evan J.
- Lai, Lilin
- Floyd, Katharine
- Rouphael, Nadine G.
- Zarnitsyna, Veronika
- Roberts, Paul C.
- Beigel, John H.
- Jackson, Lisa A.
- Neuzil, Kathleen M.
- Bennett, Hamilton
- Leav, Brett
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-06-10
- Volume
- 384
- Issue
- 23
- Pages
- 2259-2261
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8524784
- OpenAlex
- W3142193311
- Cited by
- 673
- References
- 6
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 40 · 2023: 104 · 2022: 287 · 2021: 199
- FWCI
- 49.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Covid-Catalyst-I3 Funds from the Woodruff Health Sciences Center and Emory School of Medicine
- North Carolina Policy Collaboratory at the University of North Carolina at Chapel Hill
- North Carolina Coronavirus Relief Fund
- Coalition for Epidemic Preparedness Innovations
- Georgia Research Alliance
- National Institute of Allergy and Infectious Diseases (AI149644, HHSN272201500002C, P51 OD011132, UM1AI148373, UM1AI148576, UM1AI148684, UM1Al148684-01S1)
- National Center for Advancing Translational Sciences (UL1 TR002243)
- Dolly Parton COVID-19 Research Fund
- Emory Executive Vice President for Health Affairs Synergy Fund award
- Center for Childhood Infections and Vaccines
- Children’s Healthcare of Atlanta
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccination, antibody persistence, humoral immune response, Moderna vaccine, booster vaccination, SARS-CoV-2 antibodies
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adult, Aged, Antibodies, Viral, Half-Life, Humans, Middle Aged, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
